Abstract 2299: Development of a novel next-generation sequencing (NGS)-based assay for measurable residual disease (MRD) in FLT3 -ITD acute myeloid leukemia (AML) and its potential clinical application in patients
Shi, Wenge, Laing, Christian, Ding, Wei, Mycoco, Marc, Lameh, Jelveh, Pollner, Reinhold
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article